153 related articles for article (PubMed ID: 27648860)
1. Identification and characterization of a novel nanobody against human placental growth factor to modulate angiogenesis.
Arezumand R; Mahdian R; Zeinali S; Hassanzadeh-Ghassabeh G; Mansouri K; Khanahmad H; Namvar-Asl N; Rahimi H; Behdani M; Cohan RA; Eavazalipour M; Ramazani A; Muyldermans S
Mol Immunol; 2016 Oct; 78():183-192. PubMed ID: 27648860
[TBL] [Abstract][Full Text] [Related]
2. Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation.
Nikooharf A; Arezumand R; Mansouri K; Khoshi AH; Namdar Ahmadabad H
Mol Biotechnol; 2020 Dec; 62(11-12):580-588. PubMed ID: 32975735
[TBL] [Abstract][Full Text] [Related]
3. PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.
Zins K; Kovatchki D; Lucas T; Abraham D
Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27669225
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting angiogenesis with human single-chain variable fragment antibody targeting VEGF.
Hosseini H; Rajabibazl M; Ebrahimizadeh W; Dehbidi GR
Microvasc Res; 2015 Jan; 97():13-8. PubMed ID: 25250517
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of a human nanobody against VEGFR-2.
Ma L; Gu K; Zhang CH; Chen XT; Jiang Y; Melcher K; Zhang J; Wang M; Xu HE
Acta Pharmacol Sin; 2016 Jun; 37(6):857-64. PubMed ID: 27108602
[TBL] [Abstract][Full Text] [Related]
6. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library.
Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y
J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of an anti-delta like ligand-4 Nanobody to induce non-productive angiogenesis.
Baharlou R; Tajik N; Habibi-Anbouhi M; Shokrgozar MA; Zarnani AH; Shahhosseini F; Behdani M
Anal Biochem; 2018 Mar; 544():34-41. PubMed ID: 29246751
[TBL] [Abstract][Full Text] [Related]
8. Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.
Kazemi-Lomedasht F; Behdani M; Habibi-Anbouhi M; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2016 Jun; 35(3):167-71. PubMed ID: 27167350
[TBL] [Abstract][Full Text] [Related]
9. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D
Biochem Biophys Res Commun; 2014 Mar; 446(1):132-6. PubMed ID: 24569074
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.
Kazemi-Lomedasht F; Behdani M; Bagheri KP; Habibi-Anbouhi M; Abolhassani M; Arezumand R; Shahbazzadeh D; Mirzahoseini H
Mol Immunol; 2015 May; 65(1):58-67. PubMed ID: 25645505
[TBL] [Abstract][Full Text] [Related]
11. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
[TBL] [Abstract][Full Text] [Related]
12. Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF.
Ebrahimizadeh W; Mousavi Gargari SL; Javidan Z; Rajabibazl M
Appl Biochem Biotechnol; 2015 Aug; 176(7):1985-95. PubMed ID: 26054617
[TBL] [Abstract][Full Text] [Related]
13. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
14. Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications.
Yan J; Li G; Hu Y; Ou W; Wan Y
J Transl Med; 2014 Dec; 12():343. PubMed ID: 25496223
[TBL] [Abstract][Full Text] [Related]
15. Oligoclonal selection of nanobodies targeting vascular endothelial growth factor.
Ahadi M; Ghasemian H; Behdani M; Kazemi-Lomedasht F
J Immunotoxicol; 2019 Dec; 16(1):34-42. PubMed ID: 30409071
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel neutralizing single-chain antibodies against vascular endothelial growth factor receptor 2.
Erdag B; Balcioglu BK; Bahadir AO; Serhatli M; Kacar O; Bahar A; Seker UO; Akgun E; Ozkan A; Kilic T; Tamerler C; Baysal K
Biotechnol Appl Biochem; 2011; 58(6):412-22. PubMed ID: 22172104
[TBL] [Abstract][Full Text] [Related]
17. Selection and characterization of specific nanobody against neuropilin-1 for inhibition of angiogenesis.
Naderi S; Roshan R; Ghaderi H; Behdani M; Mahmoudi S; Habibi-Anbouhi M; Shokrgozar MA; Kazemi-Lomedasht F
Mol Immunol; 2020 Dec; 128():56-63. PubMed ID: 33070092
[TBL] [Abstract][Full Text] [Related]
18. A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis.
Karami E; Sabatier JM; Behdani M; Irani S; Kazemi-Lomedasht F
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1233-1239. PubMed ID: 32441172
[TBL] [Abstract][Full Text] [Related]
19. A high affinity nanobody against endothelin receptor type B: a new approach to the treatment of melanoma.
Ji L; Dong C; Fan R; Qi S
Mol Biol Rep; 2020 Mar; 47(3):2137-2147. PubMed ID: 32080807
[TBL] [Abstract][Full Text] [Related]
20. Development of protective agent against Hottentotta saulcyi venom using camelid single-domain antibody.
Darvish M; Behdani M; Shokrgozar MA; Pooshang-Bagheri K; Shahbazzadeh D
Mol Immunol; 2015 Dec; 68(2 Pt B):412-20. PubMed ID: 26468036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
